Switch theme
Sign up to access all valuation multiples
United Laboratories International Holdings Ltd is a drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Majority of the company's sales are generated in China, followed by Europe, India and other countries.
2006
15K+
LTM Revenue $2.1B
LTM EBITDA $591M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
United Laboratories International has a last 12-month revenue of $2.1B and a last 12-month EBITDA of $591M.
In the most recent fiscal year, United Laboratories International achieved revenue of $1.8B and an EBITDA of $511M.
United Laboratories International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See United Laboratories International valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.8B | XXX | XXX | XXX |
| Gross Profit | $542M | $639M | XXX | XXX | XXX |
| Gross Margin | 37% | 36% | XXX | XXX | XXX |
| EBITDA | $340M | $511M | XXX | XXX | XXX |
| EBITDA Margin | 23% | 29% | XXX | XXX | XXX |
| Net Profit | $127M | $203M | XXX | XXX | XXX |
| Net Margin | 9% | 12% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, United Laboratories International's stock price is HKD 13 (or $2).
United Laboratories International has current market cap of HKD 24.2B (or $3.1B), and EV of HKD 20.8B (or $2.7B).
See United Laboratories International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $3.1B | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, United Laboratories International has market cap of $3.1B and EV of $2.7B.
United Laboratories International's trades at 1.4x LTM EV/Revenue multiple, and 4.9x LTM EBITDA.
Analysts estimate United Laboratories International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for United Laboratories International and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | XXX | XXX |
| P/E | 9.0x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 21.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpUnited Laboratories International's NTM/LTM revenue growth is 6%
United Laboratories International's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $26K for the same period.
Over next 12 months, United Laboratories International's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate United Laboratories International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for United Laboratories International and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 35% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $26K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 22% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
United Laboratories International acquired XXX companies to date.
Last acquisition by United Laboratories International was XXXXXXXX, XXXXX XXXXX XXXXXX . United Laboratories International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was United Laboratories International founded? | United Laboratories International was founded in 2006. |
| Where is United Laboratories International headquartered? | United Laboratories International is headquartered in Hong Kong. |
| How many employees does United Laboratories International have? | As of today, United Laboratories International has 15K+ employees. |
| Is United Laboratories International publicy listed? | Yes, United Laboratories International is a public company listed on HKG. |
| What is the stock symbol of United Laboratories International? | United Laboratories International trades under 03933 ticker. |
| When did United Laboratories International go public? | United Laboratories International went public in 2007. |
| Who are competitors of United Laboratories International? | Similar companies to United Laboratories International include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of United Laboratories International? | United Laboratories International's current market cap is $3.1B |
| What is the current revenue of United Laboratories International? | United Laboratories International's last 12-month revenue is $2.1B. |
| What is the current EBITDA of United Laboratories International? | United Laboratories International's last 12-month EBITDA is $591M. |
| What is the current EV/Revenue multiple of United Laboratories International? | Current revenue multiple of United Laboratories International is 1.4x. |
| What is the current EV/EBITDA multiple of United Laboratories International? | Current EBITDA multiple of United Laboratories International is 4.9x. |
| What is the current revenue growth of United Laboratories International? | United Laboratories International revenue growth between 2023 and 2024 was 21%. |
| Is United Laboratories International profitable? | Yes, United Laboratories International is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
